SillaJen, Inc.
Overview
SillaJen, Inc. is involved in the development of oncolytic immunotherapeutics, specifically focusing on products like Pexa-Vec, which is engineered to selectively infect and replicate in cancer cells.
Therapeutic areas
FDA compliance signals
No FDA recalls, Warning Letters, or Form 483 observations are linked to SillaJen, Inc. in our records. PharmaTek screens the full directory against live FDA enforcement data.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.